 When the randomized allocation requires continuation on the same product control, the AED products currently taken will be continued unaltered, with the same dosing regimen and times of administration. No changes in concomitant treatments will be allowed during the 56 days of the study, although addition, withdrawal or dose modification of drugs not interacting pharmacokinetically with the medications taken by the subject will be permitted. 